The FDA recently granted 510(k) clearance for ResurFX, a new fractional non-ablative laser module from Lumenis. ResurFX is the latest application module for the company's M22 platform, expanding its capabilities to perform true fractional non-ablative skin resurfacing.

ResurFX uses a 1565 nm fiber laser and a CoolScan scanner, which, according to Lumenis, enables a homogeneous and uniform pattern of coagulation columns, and requires only one pass, which. This feature saves practitioners' time and helps protect the patient's skin. The scanner also allows the user to choose from more than 600 combinations of shape, size and density for optimal treatment and results. CoolScan uses a proprietary algorithm that places each fractional spot in a controlled, non-sequential manner allowing the tissue to relax between pulses and providing protection from overheating.

“As a dermatologist, I'm always looking for laser treatments that strike the right balance between efficacy and patient comfort,” said Dr. Arielle N. B. Kauvar, MD, Director, New York Laser & Skin Care, in a statement. “With ResurFX, we have a solution that improves facial and body skin tone and texture with minimal discomfort and downtime.”

The M22 platform combines three gold-standard technologies covering more than 30 indications in one system: Intense Pulsed Light (IPL) with Optimal Pulse Technology, Multi-spot Nd:YAG and now the ResurFX for a complete aesthetic workstation.